Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A GINECO Phase II Trialo Assessing the Safety and the Efficacy of the Bevacizumab, Olaparib and Durvalumab (MEDI 4736) Combination in Patients With Advanced Epithelial Ovarian Cancer in Relapse

NCT04015739 is registered in ClinicalTrials.gov with ARCAGY/ GINECO GROUP as lead sponsor.

NCT NCT04015739
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04015739 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A GINECO Phase II Trialo Assessing the Safety and the Efficacy of the Bevacizumab, Olaparib and Durvalumab (MEDI 4736) Combination in Patients With Advanced Epithelial Ovarian Cancer in Relapse
Lead sponsor
ARCAGY/ GINECO GROUP
Phase
Phase 2
Overall status
Unknown status
Start date
March 1, 2019
Completion date
January 29, 2024
Enrollment
74 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial ovarian cancer, relapse